Treatment with Ang-(1–7)/MasR agonists mitigated cognitive impairment in this model while simultaneously increasing the levels of these pleotropic, and some putative neuroprotective cytokines, some of which are correlated to decreases blood NfL levels. This evidence concerns the gene MAS1L and Cognitive impairment.